Abiopharma

JADE BIOSCIENCES, INC. (JBIO)

Symbol	JBIO
Name	JADE BIOSCIENCES, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	221 CRESCENT ST.,BUILDING 23,SUITE 105, WALTHAM, Massachusetts, 02453, United States
Telephone	+1 781 312-3013
Fax	—
Email	—
Website	https://www.aerovatetx.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001798749
Description	Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the cytokine APRIL for immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jades pipeline also includes two undisclosed antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. Additional info from NASDAQ: Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the cytokine APRIL for immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jades pipeline also includes two undisclosed antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

2026-06-27 01:20

Eisner Mark 🟢 acquired 47.7K shares (1 derivative) of Jade Biosciences, Inc. (JBIO) at $21.81 ($1.0M) Transaction Date: Jun 25, 2026 | Filing ID: 286434

2026-06-26 22:12

New Form 3 - Jade Biosciences, Inc. Filed: 2026-06-26 AccNo: 0001193125-26-286421 Size: 12 KB

2026-06-26 11:15

(10% Negative) JADE BIOSCIENCES, INC. (JBIO) Announces Delay in Development Trials for Immunology Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

2026-06-26 11:00

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

2026-06-11 20:47

CAIN CHRISTOPHER W. 🟢 acquired 34.8K shares (1 derivative) of Jade Biosciences, Inc. (JBIO) at $15.22 Transaction Date: Jun 09, 2026 | Filing ID: 267764

2026-06-11 20:42

DOBMEIER ERIC 🟢 acquired 34.8K shares (1 derivative) of Jade Biosciences, Inc. (JBIO) at $15.22 Transaction Date: Jun 09, 2026 | Filing ID: 267739

2026-06-11 20:41

Klein Lawrence Otto 🟢 acquired 34.8K shares (1 derivative) of Jade Biosciences, Inc. (JBIO) at $15.22 Transaction Date: Jun 09, 2026 | Filing ID: 267735

2026-06-11 20:37

Lavelle Erin 🟢 acquired 34.8K shares (1 derivative) of Jade Biosciences, Inc. (JBIO) at $15.22 Transaction Date: Jun 09, 2026 | Filing ID: 267708

2026-06-11 20:37

Fairmount Funds Management LLC 🟢 acquired 34.8K shares (1 derivative) of Jade Biosciences, Inc. (JBIO) at $15.22 Transaction Date: Jun 09, 2026 | Filing ID: 267706

2026-06-11 20:28

(30% Negative) JADE BIOSCIENCES, INC. (JBIO) Files Form 8-K

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07541287	A Study of JADE101 in Participants With Immunoglobulin A Nephropathy	Phase2	IgA Nephropathy	Recruiting	2026-05-19	2029-04-01	ClinicalTrials.gov
NCT07533955	A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis	Phase1	Rhematoid Arthritis	Recruiting	2026-05-19	2028-10-01	ClinicalTrials.gov
NCT07525947	A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Partici…	Phase1	Healthy Volunteers (HV)	Recruiting	2026-05-01	2027-05-01	ClinicalTrials.gov
NCT07059312	A Phase 1 Study of JADE101 in Healthy Participants	Phase1	Healthy Volunteers	Active_Not_Recruiting	2025-08-17	2026-10-01	ClinicalTrials.gov
NCT03452280	Validation of the JADE wRAP™, a Novel Blood Pressure Measurement Device, Using …	—	Blood Pressure	Unknown	2017-12-18	2021-12-31	ClinicalTrials.gov

Total clinical trials: 5

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
JADE101	Other	Phase PHASE1	Healthy Volunteers (HV)	RECRUITING	NCT07525947
Placebo	Other	Phase PHASE1	Rhematoid Arthritis	RECRUITING	NCT07533955
JADE201	Other	Phase PHASE1	Rhematoid Arthritis	RECRUITING	NCT07533955
JADE101	Other	Phase PHASE2	IgA Nephropathy	RECRUITING	NCT07541287
JADE101	Other	Phase PHASE1	Healthy Volunteers (HV)	RECRUITING	NCT07525947
JADE101	Other	Phase PHASE1	Healthy Volunteers (HV)	RECRUITING	NCT07525947
JADE101	Other	Phase PHASE1	Healthy Volunteers (HV)	RECRUITING	NCT07525947
JADE101	Other	Phase PHASE1	Healthy Volunteers (HV)	RECRUITING	NCT07525947
JADE101	Other	Phase PHASE1	Healthy Volunteers (HV)	RECRUITING	NCT07525947
JADE101	Other	Phase PHASE1	Healthy Volunteers (HV)	RECRUITING	NCT07525947
Placebo	Other	Phase PHASE1	Healthy Volunteers	ACTIVE_NOT_RECRUITING	NCT07059312
JADE101	Other	Phase PHASE1	Healthy Volunteers	ACTIVE_NOT_RECRUITING	NCT07059312
Placebo	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE201	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE101	Other	Phase PHASE2	IgA Nephropathy	NOT_YET_RECRUITING	NCT07541287
Placebo	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE201	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE101	Other	Phase PHASE2	IgA Nephropathy	NOT_YET_RECRUITING	NCT07541287
JADE101	Other	Phase PHASE2	IgA Nephropathy	NOT_YET_RECRUITING	NCT07541287
Placebo	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE201	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE101	Other	Phase PHASE2	IgA Nephropathy	NOT_YET_RECRUITING	NCT07541287
Placebo	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE201	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE101	Other	Phase PHASE2	IgA Nephropathy	NOT_YET_RECRUITING	NCT07541287
Placebo	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE201	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE101	Other	Phase PHASE2	IgA Nephropathy	NOT_YET_RECRUITING	NCT07541287
Placebo	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE201	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE101	Other	Phase PHASE2	IgA Nephropathy	NOT_YET_RECRUITING	NCT07541287
Placebo	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE201	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE101	Other	Phase PHASE2	IgA Nephropathy	NOT_YET_RECRUITING	NCT07541287
Placebo	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE201	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
Placebo	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE201	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
Placebo	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE201	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
Placebo	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
JADE201	Other	Phase PHASE1	Rhematoid Arthritis	NOT_YET_RECRUITING	NCT07533955
Placebo	DRUG	Phase PHASE1	Healthy Volunteers	ACTIVE_NOT_RECRUITING	NCT07059312
JADE101	DRUG	Phase PHASE1	Healthy Volunteers	ACTIVE_NOT_RECRUITING	NCT07059312

Total products: 44